Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates anti-inflammatory efficacy of an oral RIPK1 inhibitor in a colitis mouse model, indicating therapeutic potential for ulcerative colitis.
Especially, it was able to exhibit remarkable anti-inflammatory treatment efficacy in a DSS-induced mouse model of UC. Taken together, the highly potent, selective, orally active anti-necroptosis inhibitor represents promising candidate for clinical treatment of UC.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: